
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has achieved a significant operational milestone by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, which enables the company to commence U.S. manufacturing of its proprietary Alpha DaRT technology in 2026. The company's strong cash position further supports its capability to develop innovative solutions in oncology, targeting a highly unmet medical need. Despite a net loss of $11.7 million, slightly higher than expected, the potential effectiveness of Alpha DaRT in producing systemic responses from localized treatment suggests promising long-term growth prospects for Alpha Tau Medical.
Bears say
Alpha Tau Medical reported a net loss of $11.7 million in the third quarter of 2025, highlighting the ongoing financial challenges the company faces as it operates at a clinical stage. Significant risks loom over its Alpha DaRT technology, including potential failure in clinical trials, the inability to secure regulatory approval in the U.S., and challenges related to market size and competition, all of which could hinder potential commercial success. Additionally, the company may face dilution risk that could undermine shareholder value, further contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares